Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

DISEASE CHARACTERISTICS: * Diagnosis of relapsed or refractory multiple myeloma * Measurable or evaluable disease as defined by ≥ 1 of the following: * Serum monoclonal protein ≥ 1.0 g by protein electrophoresis * Monoclonal protein ≥ 200 mg by 24-hour urine electrophoresis * Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio * Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease) * No concurrent amyloidosis PATIENT CHARACTERISTICS: * ECOG performance status (PS) 0 or 1 * ECOG PS 2 based on immobility from myeloma bone disease alone allowed at the discretion of treating physician * Creatinine ≤ 2.0 mg/dL * ANC ≥ 1,000/mm³ * Platelet count ≥ 75,000/mm³ * Hemoglobin ≥ 8.0 g/dL * Proteinuria ≤ 1 g/dL by 24-hour urine collection (excluding monoclonal protein) * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 4 weeks after completion of study treatment * No bleeding diathesis * No hypertension (defined as BP \> 150/100 mm Hg) * No active bleeding, healing or nonhealing wound, ulcer, or bone fracture (excluding fractures secondary to myeloma) * No active ulcerative disease including, but not limited to, any of the following: * Peptic ulcer disease * Ulcerative esophagitis * Ulcerative colitis * Crohn's disease * LVEF ≥ 50% by 2-dimensional ECHO or MUGA scan * No NYHA class III or IV heart disease * No other active malignancy except for nonmelanoma skin cancer or in situ cervical or breast cancer * No active infection * No other comorbidity that would interfere with study compliance * No transient ischemic attack, cerebrovascular accident, or myocardial infarction within the past year * No abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within the past 6 months * No significant traumatic injury within the past 28 days PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No more than 2 prior antimyeloma treatment courses, except for bisphosphonates * No standard or experimental drug therapy, other than ongoing bisphosphonate treatment and/or epoetin alfa, within the past 28 days * No experimental non-drug therapy within the past 28 days * Palliative radiation therapy within the past 28 days allowed provided ≤ 3 sites of bone disease was irradiated * No prior bevacizumab or other experimental antiangiogenic agents other than thalidomide or lenalidomide * No minor surgical procedures, fine-needle aspiration, or core biopsies within the past 7 days * No major surgical procedure or open biopsy within the past 28 days * No concurrent corticosteroids * Chronic steroids ≤ 20 mg/day (prednisone equivalent) for disorders other than myeloma (i.e., adrenal insufficiency, rheumatoid arthritis) allowed * No other concurrent investigational therapy * No other concurrent systemic antineoplastic therapy including, but not limited to, the following: * Cytotoxic chemotherapy * Immunotherapy * Hormonal therapy * Monoclonal antibody therapy * Concurrent bisphosphonates allowed